Noven, Rhone-Poulenc Rorer regulatory update

RPR's Menorest received marketing approval in Germany as a hormone replacement therapy in treating symptoms associated with menopause. Approved doses include 37.5, 50 and 75 mgs per day. Using NOVN's ...